Keocyt
Keocyt is a privately held French pharmaceutical product development company headquartered in Malakoff, France, founded in 2006, operating with a 1-10 employee team focused on pharmaceutical development.
- Company typePrivate
- Founded2006
- HeadquartersMalakoff, France
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Keocyt does
Keocyt is a privately held French for-profit company that develops pharmaceutical products, headquartered in Malakoff, France, and founded in 2006. The firmographic profile indicates a small organization with 1-10 employees and no publicly disclosed parent, subsidiaries, or ownership structure. The firm's public footprint is limited to its website (keocyt.com), with no additional operational, pipeline, partnership, or financial details provided in the source material.
The aggregated input contains extensive pharmaceutical industry data — including €744M in 2024 net turnover, six European subsidiaries, manufacturing sites in Asia and the Americas, a B Corp certification, 2025 acquisitions of Regis Technologies and Caprelsa (vandetanib), and a licensing agreement for an IGF-1 deficiency treatment — but the source explicitly states this material pertains to Esteve Pharmaceuticals S.A.S. and that no relationship between Keocyt and Esteve is established in the provided data. Accordingly, this profile reflects only the information directly attributable to Keocyt, and any substantive analysis of therapeutic focus, revenue mechanics, go-to-market, or competitive positioning is constrained by the absence of company-specific data beyond the basic firmographic record.
Keocyt firmographics
Firmographics- Name
- Keocyt
- Legal name
- Esteve Pharmaceuticals S.A.S.
- Website
- https://keocyt.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Keocyt is a privately held French pharmaceutical product development company headquartered in Malakoff, France, founded in 2006, operating with a 1-10 employee team focused on pharmaceutical development.
- Ownership category
- akta.pro rank
Keocyt industry classification
Industry- Product category
- Pharmaceutical Products
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Pharmaceutical Distributors (HLAIAJAB)
Keywords
Where Keocyt is headquartered
LocationHeadquarters
- HQ city
- Malakoff
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Keocyt business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Revenue model
- Pharmaceutical Product Sales: Revenue generated from the sale of proprietary and licensed pharmaceutical medications across therapeutic areas including rare diseases and specialized cancer treatments. The company operates internationally through six European subsidiaries and manufacturing sites in Asia and the Americas.
- Contract Manufacturing Services: Development and manufacturing services for active pharmaceutical ingredients provided to pharmaceutical partners under contract. This includes preclinical through commercial-scale manufacturing capabilities.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Keocyt product offering
Product offeringCore offering
Keocyt develops pharmaceutical products. The company is a small, privately-held for-profit pharmaceutical firm founded in 2006 and headquartered in Malakoff, France, with 1-10 employees.
Product overview
ESTEVE is an international dynamic pharmaceutical company focused on highly specialized treatments for unmet medical and patient needs. The company operates through two main product lines: therapeutic areas and medications. Recent expansion includes the acquisition of Regis Technologies to establish small molecule active pharmaceutical ingredient development and manufacturing capabilities in the United States, the acquisition of Caprelsa (vandetanib) for medullary thyroid cancer, and licensing of a biological treatment for severe primary IGF-1 deficiency in children.
Differentiator
Problem solved
Functional benefit
Companies that use Keocyt
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Keocyt technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Keocyt partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Regis TechnologiescoreEsteve acquired Regis Technologies to extend its contract development and manufacturing services for active pharmaceutical ingredients of small molecules, from preclinical phase through commercial manufacturing, establishing a presence in the United States.
Scale indicators2 records
Keocyt competitors and assessment
Company assessmentDirect peers
- Almirall: Spanish-headquartered specialty pharmaceutical company focused on dermatology and rare conditions with European commercial reach. Comparable Iberian base and specialty-pharma commercial model.
- Cambrex: US-based small-molecule API CDMO with capabilities spanning preclinical through commercial manufacturing. Directly comparable to the Regis Technologies–anchored CDMO leg of the subject company.
- Recipharm: Swedish-headquartered CDMO and specialty pharmaceutical manufacturer offering small-molecule API development and manufacturing services across Europe. Closely mirrors the integrated CDMO + specialty pharma model described in the source data.
- Recordati: Italian specialty pharmaceutical group with European subsidiary network, focused on rare diseases and specialty therapeutics. Highly comparable geographic footprint and rare-disease commercial strategy.
Broad incumbents
- Ipsen: French-headquartered specialty pharmaceutical company with a strong oncology and rare-disease focus across Europe. Comparable therapeutic-area emphasis and European institutional sales model.
- Stada Arzneimittel: German-headquartered European specialty and generics pharmaceutical group with multi-country subsidiary network. Comparable multi-European-subsidiary distribution model and specialty focus.
- Catalent: Major global CDMO offering development and manufacturing services across multiple modalities. Comparable to the CDMO services leg, though broader and substantially larger in scale.
Regional players
- Faes Farma: Spanish specialty pharmaceutical company with European and Latin American presence in prescription and OTC products. Comparable Iberian specialty-pharma positioning and international subsidiary structure.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat1 record
Key risks5 records
Key highlights6 records
Customer concentration
Keocyt social profiles
Digital presenceKeocyt financial estimates
Financial estimateRevenue estimate
Valuation estimate
Keocyt leadership team
Management profileNumber of profiles
Keocyt funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Keocyt M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Keocyt
What does Keocyt do?
Keocyt develops pharmaceutical products. The company is a small, privately-held for-profit pharmaceutical firm founded in 2006 and headquartered in Malakoff, France, with 1-10 employees.
Is Keocyt a public or private company?
Keocyt is a private company. It is classified as unknown and is currently operating.
When was Keocyt founded?
Keocyt was founded in 2006. It employs 1 to 10 people.
Where is Keocyt based?
Keocyt is headquartered in Malakoff, France, in the Europe region.
How does Keocyt make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are contract Manufacturing Services.
Who are Keocyt's main competitors?
Direct peers on record are Almirall, Cambrex, Recipharm and Recordati. Broad incumbents are Ipsen, Stada Arzneimittel and Catalent. Faes Farma is listed as a regional player.
Does Keocyt have an API?
No public API is recorded for Keocyt.
What industry is Keocyt in?
Keocyt's product category is Pharmaceutical Products. Its primary akta.pro industry code is HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 325412 and its SIC code is 2834.